LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD
Market Cap: 45.8m USD

LAVA Therapeutics NV
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Capital Expenditures
-$23k
CAGR 3-Years
69%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Capital Expenditures
-$630k
CAGR 3-Years
57%
CAGR 5-Years
45%
CAGR 10-Years
-7%
ProQR Therapeutics NV
NASDAQ:PRQR
Capital Expenditures
-€627k
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
10%
Uniqure NV
NASDAQ:QURE
Capital Expenditures
-$360k
CAGR 3-Years
72%
CAGR 5-Years
47%
CAGR 10-Years
27%
argenx SE
XBRU:ARGX
Capital Expenditures
-$68.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Capital Expenditures
-$607k
CAGR 3-Years
53%
CAGR 5-Years
12%
CAGR 10-Years
-26%
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.52 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Capital Expenditures?
Capital Expenditures
-23k USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Capital Expenditures amounts to -23k USD.

What is LAVA Therapeutics NV's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
50%

Over the last year, the Capital Expenditures growth was 97%. The average annual Capital Expenditures growth rates for LAVA Therapeutics NV have been 69% over the past three years , 50% over the past five years .

Back to Top